Management of severe abdominal infections

Recent Patents on Anti-Infective Drug Discovery

Volumn 4, Issue 1, 2009, Pages 57-65

  Hasper, Dietrich ^a   Schefold, Joerg C ^a   Baumgart, Daniel C ^b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CEFTAROLINE; CEFTOBIPROLE; CILASTATIN PLUS IMIPENEM; DALBAVANCIN; DORIPENEM; LINEZOLID; MEROPENEM; MOXIFLOXACIN; TIGECYCLINE; VANCOMYCIN;

ABDOMINAL INFECTION; ABDOMINAL PAIN; ABDOMINAL RADIOGRAPHY; ABDOMINAL TENDERNESS; ABSCESS; BACTERIUM CULTURE; CHOLANGITIS; CLINICAL FEATURE; CLINICAL TRIAL; COMMUNICABLE DISEASE; COMPUTER ASSISTED TOMOGRAPHY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG PENETRATION; HIGH RISK PATIENT; HOSPITAL INFECTION; HUMAN; IMMUNE DEFICIENCY; INFECTION RISK; INTESTINE FLORA; INTRAPERITONEAL ABSCESS; LIVER ABSCESS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PANCREAS ABSCESS; PERITONITIS; PRIORITY JOURNAL; REVIEW; SKIN INFECTION; ABDOMINAL ABSCESS; CROSS INFECTION; MICROBIOLOGY;

ABDOMINAL ABSCESS; CHOLANGITIS; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; HUMANS; LIVER ABSCESS; PERITONITIS;

EID: 62749123020     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489109787236265     Document Type: Review

References (72)

1. Hao WL, Lee YK. Microflora of the gastrointestinal tract: A review. Methods Mol Biol 2004; 268: 491-502.
2. Hooper LV, Wong MH, Thelin A, Hansson L, Falk PG, Gordon JI. Molecular analysis of commensal host-microbial relationships in the intestine. Science 2001; 291: 881-884.
3. Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care 2002; 5: 685-694.
4. Seiler CA, Brugger L, Forssmann U, Baer HU, Buchler MW. Conservative surgical treatment of diffuse peritonitis. Surgery 2000; 127: 178-184.
5. Kumar A, Roberts D, Wood KE, et al. Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock. Crit Care Med 2006; 34: 1589-1596.
6. Christou L, Pappas G, Falagas ME. Bacterial infection-related morbidity and mortality in cirrhosis. Am J Gastroenterol 2007; 102: 1510-1517.
7. Tandon P, Garcia-Tsao G. Bacterial infections, sepsis, and multiorgan failure in cirrhosis. Semin Liver Dis 2008; 28: 26-42.
8. Fasolato S, Angeli P, Dallagnese L, et al. Renal failure and bacterial infections in patients with cirrhosis: Epidemiology and clinical features. Hepatology 2007; 45: 223-229.
9. Salles JM, Salles MJ, Moraes LA, Silva MC. Invasive amebiasis: An update on diagnosis and management. Expert Rev Anti Infect Ther 2007; 5: 893-901.
10. Blot S, De Waele JJ. Critical issues in the clinical management of complicated abdominal infections. Drugs 2005; 65: 1611-1620.
11. Chen J, Li LF, Guan XD, et al. The drug resistance of pathogenic bacteria of nosocomial infections in surgical intensive care unit. Zhonghua Wai Ke Za Zhi 2006; 44: 1189-1192.
12. Lorber B, Swenson RM. The bacteriology of abdominal infections. Surg Clin North Am 1975; 55: 1349-1354.
13. Aseeri M, Schroeder T, Kramer J, Zackula R. Gastric acid suppression by proton pump inhibitors as a risk factor for Clostridium difficile-associated diarrhea in hospitalized patients. Am J Gastroenterol 2008; 103(9): 2308-2313.
14. Pohl D, Fox M, Fried M, et al. Do We need gastric acid? Digestion 2008; 77: 184-197.
15. Gorbach SL. Intestinal microflora. Gastroenterology 1971; 60: 1110-1129.
16. Brook I. Aerobic and anaerobic microbiology of biliary tract disease. J Clin Microbiol 1989; 27: 2373-2375.
17. Brook I, Frazier EH. Microbiology of liver and spleen abscesses. J Med Microbiol 1998; 47: 1075-1080.
18. Brook I, Frazier EH. Aerobic and anaerobic microbiology of retroperitoneal abscesses. Clin Infect Dis 1998; 26: 938-941.
19. Bennion RS, Baron EJ, Thompson JE Jr, et al. The bacteriology of gangrenous and perforated appendicitis revisited. Ann Surg 1990; 211: 165-171.
20. Bennion RS, Thompson JE, Baron EJ, Finegold SM. Gangrenous and perforated appendicitis with peritonitis: Treatment and bacteriology. Clin Ther 1990; 12 Suppl C: 31-44.
21. Baron EJ, Bennion R, Thompson J, et al. A microbiological comparison between acute and complicated appendicitis. Clin Infect Dis 1992; 14: 227-231.
22. Brook I, Frazier EH. Aerobic and anaerobic microbiology in abdominal infections associated with diverticulitis. J Med Microbiol 2000; 49: 827-830.
23. Barie PS, Christou NV, Dellinger EP, Rout WR, Stone HH, Waymack JP. Pathogenicity of the Enterococcus in surgical infections. Ann Surg 1990; 212: 155-159.
24. Burnett RJ, Haverstock DC, Dellinger EP, et al. Definition of the role of Enterococcus in intraabdominal infection: analysis of a prospective randomized trial. Surgery 1995; 118: 716-721.
25. Rotstein OD, Pruett TL, Simmons RL. Microbiologic features and treatment of persistent peritonitis in patients in the intensive care unit. Can J Surg 1986; 29: 247-250.
26. Sandven P, Qvist H, Skovlund E, Giercksky KE. Significance of Candida recovered from intraoperative specimens in patients with abdominal perforations. Crit Care Med 2002; 30: 541-547.
27. Montravers P, Dupont H, Gauzit R, et al. Candida as a risk factor for mortality in peritonitis. Crit Care Med 2006; 34: 646-652.
28. Antevil JL, Egan JC, Woodbury RO, Rivera L, Oreilly EB, Brown CV. Abdominal computed tomography for postoperative abscess: Is it useful during the first week? J Gastrointest Surg 2006; 10: 901-905.
29. Kokoska ER, Silen ML, Tracy TF Jr, et al. The impact of intraoperative culture on treatment and outcome in children with perforated appendicitis. J Pediatr Surg 1999; 34: 749-753.
30. Bilik R, Burnweit C, Shandling B. Is abdominal cavity culture of any value in appendicitis? Am J Surg 1998; 175: 267-270.
31. Yellin AE, Heseltine PN, Berne TV, et al. The role of Pseudomonas species in patients treated with ampicillin and Sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 1985; 161: 303-307.
32. Falagas ME, Barefoot L, Griffith J, Ruthazar R, Snydman DR. Risk factors leading to clinical failure in the treatment of abdominal or skin/soft tissue infections. Eur J Clin Microbiol Infect Dis 1996; 15: 913-921.
33. Christou NV, Turgeon P, Wassef R, Rotstein O, Bohnen J, Potvin M. Management of abdominal infections. The case for intraoperative cultures and comprehensive broad-spectrum antibiotic coverage. The Canadian Abdominal Infection Study Group. Arch Surg 1996; 131: 1193-1201.
34. Snydman DR, Jacobus NV, McDermott LA, et al. Multicenter study of in vitro susceptibility of the Bacteroides fragilis group, 1995 to 1996, with comparison of resistance trends from 1990 to 1996. Antimicrob Agents Chemother 1999; 43: 2417-2422.
35. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997; 25: 584-599.
36. Solomkin JS, Mazuski JE, Baron EJ, et al. Guidelines for the selection of anti-infective agents for complicated abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
37. Malangoni MA, Song J, Herrington J, Choudhri S, Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated abdominal infections. Ann Surg 2006; 244: 204-211.
38. Lennard ES, Dellinger EP, Wertz MJ, Minshew BH. Implications of leukocytosis and fever at conclusion of antibiotic therapy for abdominal sepsis. Ann Surg 1982; 195: 19-24.
39. Hedrick TL, Evans HL, Smith RL, et al. Can we define the ideal duration of antibiotic therapy? Surg Infect (Larchmt) 2006; 7: 419-432.
40. Basoli A, Chirletti P, Cirino E, et al. A prospective, double-blind, multicenter, randomized trial comparing ertapenem 3 vs >or=5 days in community-acquired intraabdominal infection. J Gastrointest Surg 2008; 12: 592-600.
41. Laterre PF. Progress in medical management of abdominal infection. Curr Opin Infect Dis 2008; 21: 393-398.
42. Hau T, Lippert H. [Intraperitoneal infections and immuno-suppression (author's transl)]. Zentralbl Chir 1982; 107: 65-77.
43. Franco A, Planelles M, de JJ, Paya A, Ceballos S, Olivares J. [Perforation of the acalculous gallbladder in a renal transplant recipient with CMV infection]. Nefrologia 2006; 26: 619-622.
44. Nishii T, Rino Y, Ando K, et al. Successful treatment of multiple small-bowel perforations caused by cytomegalovirus in a patient with malignant lymphoma: report of a case. Surg Today 2006; 36: 930-933.
45. Bang S, Park YB, Kang BS, et al. CMV enteritis causing ileal perforation in underlying lupus enteritis. Clin Rheumatol 2004; 23: 69-72.
46. Plevak DJ, De Ruyter ML. Intensive care of the abdominal organ transplant recipient. Seminars in Cardiothoracic and Vascular Anesthesia 1998; 2: 155-165.
47. Kollef M. Appropriate empirical antibacterial therapy for nosocomial infections: getting it right the first time. Drugs 2003; 63: 2157-2168.
48. Montravers P, Gauzit R, Muller C, Marmuse JP, Fichelle A, Desmonts JM. Emergence of antibiotic-resistant bacteria in cases of peritonitis after intraabdominal surgery affects the efficacy of empirical antimicrobial therapy. Clin Infect Dis 1996; 23: 486-494.
49. Ibrahim EH, Sherman G, Ward S, Fraser VJ, Kollef MH. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest 2000; 118: 146-155.
50. Lazarova, T., Thormann, M., Almstetter, M., Cottarel, G., Riesinger, S.W.: WO2008094507 (2008).
51. Talbot GH, Bradley J, Edwards JE Jr, Gilbert D, Scheld M, Bartlett JG. Bad bugs need drugs: An update on the development pipeline from the antimicrobial availability task force of the infectious diseases society of America. Clin Infect Dis 2006; 42: 657-668.
52. Landman D, Quale JM, Mayorga D, et al. Citywide clonal outbreak of multiresistant Acinetobacter baumannii and Pseudomonas aeruginosa in Brooklyn, NY: The preantibiotic era has returned. Arch Intern Med 2002; 162: 1515-1520.
53. Drusano GL. Infection in the intensive care unit: Beta-lactamase-mediated resistance among Enterobacteriaceae and optimal antimicrobial dosing. Clin Infect Dis 1998; 27 Suppl 1: S111-S116.
54. Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39: 55-60.
55. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004; 32: 470-485.
56. Patterson JE, Sweeney AH, Simms M, et al. An analysis of 110 serious Enterococcal infections. Epidemiology. Antibiotic susceptibility, and outcome. Medicine (Baltimore) 1995; 74: 191-200.
57. Reik R, Tenover FC, Klein E, McDonald LC. The burden of vancomycin-resistant Enterococcal infections in US hospitals, 2003 to 2004. Diagn Microbiol Infect Dis 2008.
58. Oztoprak N, Cevik MA, Akinci E, et al. Risk factors for ICUacquired methicillin-resistant Staphylococcus aureus infections. Am J Infect Control 2006; 34: 1-5.
59. Chang DC, Wilson SE. Meta-analysis of the clinical outcome of carbapenem monotherapy in the adjunctive treatment of abdominal infections. Am J Surg 1997; 174: 284-290.
60. Birmingham MC, Rayner CR, Meagher AK, Flavin SM, Batts DH, Schentag JJ. Linezolid for the treatment of multidrug-resistant, gram-positive infections: Experience from a compassionate-use program. Clin Infect Dis 2003; 36: 159-168.
61. Bradford PA, Weaver-Sands DT, Petersen PJ. in vitro Activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated abdominal infections. Clin Infect Dis 2005; 41 Suppl 5: S315-S332.
62. Fomin P, Beuran M, Gradauskas A, et al. Three Hundred Six Study Group: Tigecycline is efficacious in the treatment of complicated abdominal infections. Int J Surg 2005; 3: 35-47.
63. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. The efficacy and safety of tigecycline for the treatment of complicated abdominal infections: Analysis of pooled clinical trial data. Clin Infect Dis 2005; 41 Suppl 5: S354-S367.
64. Borg MA, Scicluna E, de KM, et al. Antibiotic resistance in the southeastern Mediterranean--preliminary results from the ARMed project. Euro Surveill 2006; 11: 164-167.
65. Zhanel GG, Trapp S, Gin AS, et al. Dalbavancin and telavancin: Novel lipoglycopeptides for the treatment of Gram-positive infections. Expert Rev Anti Infect Ther 2008; 6: 67-81.
66. Crandon J, Nicolau DP. Oritavancin: A potential weapon in the battle against serious Gram-positive pathogens. Future Microbiol 2008; 3: 251-263.
67. Arimoto, H., Lu, J., Yamano, Y., Yasukata, T., Yoshida, O., Iwaki, T., Yoshida, Y., Kato, I., Morimoto, K., Yasoshima, K.: EP1818340 (2008).
68. Walsh F. Doripenem. A new carbapenem antibiotic a review of comparative antimicrobial and bactericidal activities. Ther Clin Risk Manag 2007; 3: 789-794.
69. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated abdominal infection: A phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin Ther 2008; 30: 868-883.
70. Brighty, K.E., Marfat, A., Mcleod, D.G., O'donnell, J.P., Anderson, S.R.: WO2008059367 (2008).
71. Lodise TP, Patel N, Renaud-Mutart A, Gorodecky E, Fritsche TR, Jones RN. Pharmacokinetic and pharmacodynamic profile of ceftobiprole. Diagn Microbiol Infect Dis 2008; 61: 96-102.
72. Mushtaq S, Warner M, Ge Y, Kaniga K, Livermore DM. in vitro Activity of ceftaroline (PPI-0903M, T-91825) against bacteria with defined resistance mechanisms and phenotypes. J Antimicrob Chemother 2007; 60: 300-311.